Skip to main content

Table 2 Patient HLA types and ELISpot results, showing the sum of delta (background subtracted) IFN-γ spot forming cells (SFC) at weeks 0, 16 and 65 for each patient for whom ELISpot analysis was possible.

From: A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy

Patient HLA type (peptides used) Sum of Δ IFN-γ SFC/106 PBMC
   Week 0 Week 16 Week 65
Group A   Gag Pol Nef Gag Pol Nef Gag Pol Nef
1 A1 (g1)
A2 (g2, p1, p2, p3, n1)
B7 (g8, n2)
B18 (n8)
20 20 260 0 0 150 20 10 680
16 A2, (g2, p1, p2, p3, n1)
B44 (g17, p13, p14)
50 90 110 940 850 320 740 1200 20
36 A2, (g2, p1, p2, p3)
A23, (g13)
B27, (n9)
B49 (n8)
F F F 70 60 30 230 280 370
52 A11, (g4, g5, p5, n2)
A9, (none identified)
B35A, (g14, p10)
B61 (g23, p15, n13)
670 470 295 910 405 1280 370 215 165
54 A2, (g2, p2, n1)
A11, (g5, p5)
B27, (n9)
B35A (g14, p10)
80 190 30 F F F 290 240 160
Group B   Gag Pol Nef Gag Pol Nef Gag Pol Nef
7 A2, (g2, p2, p3, n1)
A24, (g6)
B55, (g18)
B57B (g19, g20, 21, g22)
500 30 0 1310 120 20 1340 190 0
35 A3, (g3)
A32, (p8)
B7 (g8, n5)
50 110 75 130 70 25 185 135 115
57 A1, (g1)
B8 (g9, g10, g11, g12, p9, n6, n7)
490 50 130 190 30 20 450 70 120
Group C   Gag Pol Nef Gag Pol Nef Gag Pol Nef
4 A1, (g1)
A26, (g7)
B27, (n9)
B57B(g19, g20, g21, g22, n12)
220 nd 50 130 nd 40 520 nd 60
11 A1, (g1)
A2, (g2, p1, p2, p3, n1) B35A, (g14, g15, g16, p10, p11, p12, n10, n11)
B57B(g19, g20, g21, g22, n12)
3820 3140 2990 90 50 20 2820 2760 960
14 A1, (g1)
A2, (g2, p1, p2, p3, n1)
B57B,(g19, g20, g21, g22, n12)
B62 (none identified)
F F F 1140 130 20 100 30 70
34 A3, (g3)
A29, (p7)
B35A, (g14, g15, p10, n10)
B44 (g17, p13, p14)
320 100 0 F F F 520 80 10
Group D   Gag Pol Nef Gag Pol Nef Gag Pol Nef
13 A2, (g2, p1, p2, n1)
A11, (g4, p4, n2)
B8, (g9, p9, n6)
B62 (none identified)
50 20 70 730 1890 1190 390 640 240
22 A1, (g1)
A2, (g2, p2, n1)
B7, (g8, n5)
B35A (g14, g15, p10, n11)
270 80 120 F F F 60 40 260
  1. F denotes assay failure. IFN-γ (interferon-gamma), PBMC (peripheral blood mononuclear cells), SFC (spot forming cells). AHLA B35 is associated with rapid progression in HIV-1 infection. BHLA B57 is associated with slow/non progression in HIV-1 infection.